Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]